Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies

Journal of the Neurological Sciences

Volumn 345, Issue 1, 2014, Pages 26-36

  Tang, Wei ^a   Huang, Qiong ^a   Wang, Yan ^a   Wang, Zheng Yu ^a   Yao, Yu You ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; A 42; CSF; Dementia; Meta analysis; Mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANALYTIC METHOD; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FRONTOTEMPORAL DEMENTIA; HUMAN; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; PARKINSON DISEASE WITH DEMENTIA; PROTEIN CEREBROSPINAL FLUID LEVEL; PUBLICATION; PUBLISHING; REVIEW; SENSITIVITY ANALYSIS; XMAP METHOD; CEREBROSPINAL FLUID;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; DEMENTIA; HUMANS; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS;

EID: 84908215467     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.07.015     Document Type: Review

References (73)

1. A.C. van Harten, M.I. Kester, P.J. Visser, M.A. Blankenstein, Y.A. Pijnenburg, and W.M. van der Flier Tau and p-tau as CSF biomarkers in dementia: a meta-analysis Clin Chem Lab Med 49 3 2011 353 366
2. W.M. van der Flier, and P. Scheltens Epidemiology and risk factors of dementia J Neurol Neurosurg Psychiatry 76 Suppl. 5 2005 v2 v7
3. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease Neurology 34 1984 939 944
4. G.A. Jicha, E.L. Abner, F.A. Schmitt, R.J. Kryscio, K.P. Riley, and G.E. Cooper Preclinical AD Workgroup staging: pathological correlates and potential challenges Neurobiol Aging 33 3 2012 622.e1 622.e16
5. R.A. Frank, D. Galasko, H. Hampel, J. Hardy, M.J. de Leon, and P.D. Mehta Biological markers for therapeutic trials in Alzheimer's disease Neurobiol Aging 24 4 2003 521 536
6. G. Waldemar, B. Dubois, M. Emre, J. Georges, I.G. McKeith, and M. Rossor Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline Eur J Neurol 14 1 2007 e1 e26
7. M.P. Mattson Pathways towards and away from Alzheimer's disease Nature 430 2004 631 639
8. P.E. Spies, M.M. Verbeek, T. van Groen, and J.A. Claassen Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease Front Biosci 17 2012 2024 2034
9. K. Blennow, H. Zetterberg, and A.M. Fagan Fluid biomarkers in Alzheimer disease Cold Spring Harb Perspect Med 2 9 2012 a006221
10. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
11. D. Prvulovic, and H. Hampel Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease Clin Chem Lab Med 49 3 2011 367 374
12. J.H. Kang, M. Korecka, J.B. Toledo, J.Q. Trojanowski, and L.M. Shaw Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers Clin Chem 59 6 2013 903 916
13. M.S. Henry, A.P. Passmore, S. Todd, B. McGuinness, D. Craig, and J.A. Johnston The development of effective biomarkers for Alzheimer's disease: a review Int J Geriatr Psychiatry 28 4 2013 331 340
14. J. Cohen A power primer Psychol Bull 112 1992 155 159
15. R.D. Ledesma, and G. Macbeth Computing effect size measures with ViSta - the visual statistics system Tutor Quant Methods Psychol 5 2009 25 34
16. N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele, and B. Winblad Evaluation of CSF-tau and CSF-A-beta-42 as diagnostic markers for Alzheimer disease in clinical practice Arch Neurol 58 2001 373 379
17. M. Maruyama, H. Arai, M. Sugita, H. Tanji, M. Higuchi, and N. Okamura Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease Exp Neurol 172 2001 433 436
18. H. Hampel, A. Mitchell, K. Blennow, R.A. Frank, S. Brettschneider, and L. Weller Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity J Neural Transm 111 2004 247 272
19. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 3 2006 228 234
20. L. Parnetti, A. Lanari, G. Silvestrelli, E. Saggese, and P. Reboldi Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers Mech Ageing Dev 127 2 2006 129 132
21. F.H. Bouwman, W.M. van der Flier, N.S. Schoonenboom, E.J. van Elk, A. Kok, and F. Rijmen Longitudinal changes of CSF biomarkers in memory clinic patients Neurology 69 10 2007 1006 1011
22. E.S. Blom, V. Giedraitis, H. Zetterberg, H. Fukumoto, K. Blennow, and B.T. Hyman Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype Dement Geriatr Cogn Disord 27 5 2009 458 464
23. W.J. Henneman, H. Vrenken, J. Barnes, I.C. Sluimer, N.A. Verwey, and M.A. Blankenstein Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease Neurology 73 12 2009 935 940
24. W.J. Jagust, S.M. Landau, L.M. Shaw, J.Q. Trojanowski, R.A. Koeppe, and E.M. Reiman Relationships between biomarkers in aging and dementia Neurology 73 15 2009 1193 1199
25. A. Lanari, and L. Parnetti Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting Sci World J 9 2009 961 966
26. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 4 2009 403 413
27. L.G. Exalto, W.M. van der Flier, P. Scheltens, and G.J. Biessels Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic J Am Geriatr Soc 58 7 2010 1318 1321
28. M.O. Habert, L.C. de Souza, F. Lamari, N. Daragon, S. Desarnaud, and C. Jardel Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease Eur J Nucl Med Mol Imaging 37 3 2010 589 593
29. J. Nettiksimmons, D. Harvey, J. Brewer, O. Carmichael, C. DeCarli, and C.R. Jack Jr. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline Neurobiol Aging 31 8 2010 1419 1428
30. O.C. Okonkwo, M.L. Alosco, H.R. Griffith, M.M. Mielke, L.M. Shaw, and J.Q. Trojanowski Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease Arch Neurol 67 6 2010 688 696
31. M.W. Riepe, J. Karl, H. Tumani, and C.A. von Arnim Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment Dement Geriatr Cogn Disord 30 2 2010 93 100
32. J.M. Schott, J.W. Bartlett, J. Barnes, K.K. Leung, S. Ourselin, and N.C. Fox Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment Neurobiol Aging 31 8 2010 1452 1462
33. J.D. Sluimer, F.H. Bouwman, H. Vrenken, M.A. Blankenstein, F. Barkhof, and W.M. van der Flier Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study Neurobiol Aging 31 5 2010 758 764
34. J. Sundelöf, J. Sundström, O. Hansson, M. Eriksdotter-Jönhagen, V. Giedraitis, and A. Larsson Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls J Alzheimers Dis 21 2 2010 471 478
35. D. Tosun, N. Schuff, D. Truran-Sacrey, L.M. Shaw, J.Q. Trojanowski, and P. Aisen Relations between brain tissue loss, CSF biomarkers and the ApoE genetic profile: a longitudinal MRI study Neurobiol Aging 31 8 2010 1340 1354
36. P. Alexopoulos, L.H. Guo, M. Kratzer, C. Westerteicher, A. Kurz, and R. Perneczky Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers Dement Geriatr Cogn Disord 32 2011 164 170
37. R. Perneczky, A. Tsolakidou, A. Arnold, J. Diehl-Schmid, T. Grimmer, and H. Förstl CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease Neurology 77 1 2011 35 38
38. B. Schmand, P. Eikelenboom, and W.A. van Gool Alzheimer's disease neuroimaging initiative. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts J Am Geriatr Soc 59 9 2011 1705 1710
39. C. Solé-Padullés, A. Lladó, D. Bartrés-Faz, J. Fortea, R. Sánchez-Valle, and B. Bosch Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum Psychiatry Res 192 3 2011 140 146
40. L.H. Guo, C. Westerteicher, X.H. Wang, M. Kratzer, A. Tsolakidou, and M. Jiang SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer's disease Eur Arch Psychiatry Clin Neurosci 262 2012 529 534
41. F. Mouton-Liger, C. Paquet, J. Dumurgier, P. Lapalus, F. Gray, and J.L. Laplanche Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease Biol Psychiatry 71 2012 829 835
42. K. Westin, P. Buchhave, H. Nielsen, L. Minthon, S. Janciauskiene, and O. Hansson CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease PLoS One 7 1 2012 e30525
43. M. Sjögren, L. Minthon, P. Davidsson, A.K. Granérus, A. Clarberg, and H. Vanderstichele CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging J Neural Transm 107 2000 563 579
44. M. Sjögren, P. Davidsson, A. Wallin, A.K. Granérus, E. Grundström, and H. Askmark Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta amyloid induced by disparate mechanisms Dement Geriatr Cogn Disord 13 2002 112 118
45. I. Blasko, W. Lederer, H. Oberbauer, T. Walch, G. Kemmler, and H. Hinterhuber Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias Dement Geriatr Cogn Disord 21 1 2006 9 15
46. S. Engelborghs, K. Maertens, E. Vloeberghs, T. Aerts, N. Somers, and P. Mariën Neuropsychological and behavioural correlates of CSF biomarkers in dementia Neurochem Int 48 2006 286 295
47. B. Ibach, H. Binder, M. Dragon, S. Poljansky, E. Haen, and E. Schmitz Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample Neurobiol Aging 27 9 2006 1202 1211
48. D. Galimberti, E. Venturelli, C. Fenoglio, I. Guidi, C. Villa, and L. Bergamaschini Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration J Neurol 255 2008 539 544
49. P.E. Spies, D. Slats, J.M. Sjögren, B.P. Kremer, F.R. Verhey, and M.G. Rikkert The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia Curr Alzheimer Res 7 5 2010 470 476
50. N.A. Verwey, M.I. Kester, W.M. van der Flier, R. Veerhuis, H. Berkhof, and H. Twaalfhoven Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects J Alzheimers Dis 20 2 2010 445 452
51. A. Gabelle, S. Roche, C. Gény, K. Bennys, P. Labauge, and Y. Tholance Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia J Alzheimers Dis 26 3 2011 553 563
52. M.K. Herbert, M.B. Aerts, H.B. Kuiperij, J.A.H.R. Claassen, P.E. Spies, and R.A.J. Esselink Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias Alzheimers Dement 2013 10.1016/j.jalz.2013.05.1775
53. 42 and normal tau levels in dementia with Lewy bodies Neurology 54 9 2000 1875 1876
54. B. Mollenhauer, M. Bibl, J. Wiltfang, P. Steinacker, B. Ciesielczyk, and K. Neubert Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies Clin Chem Lab Med 44 2 2006 192 195
55. K. Wada-Isoe, M. Kitayama, K. Nakaso, and K. Nakashima Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study J Neurol Sci 260 2007 33 37
56. L. Parnetti, P. Tiraboschi, A. Lanari M. Peducci, C. Padiglioni, and C. D'Amore Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies Biol Psychiatry 64 10 2008 850 855
57. M. Noguchi-Shinohara, T. Tokuda, M. Yoshita, T. Kasai, K. Ono, and M. Nakagawa CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease Brain Res 1251 2009 1 6
58. K. Kasuga, T. Tokutake, A. Ishikawa, T. Uchiyama, T. Tokuda, and O. Onodera Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease J Neurol Neurosurg Psychiatry 81 6 2010 608 610
59. E. Mulugeta, E. Londos, C. Ballard G. Alves, H. Zetterberg, and K. Blennow CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies J Neurol Neurosurg Psychiatry 82 2 2011 160 164
60. M. Wennström, E. Londos, L. Minthon, and H.M. Nielsen Altered CSF orexin and α-synuclein levels in dementia patients J Alzheimers Dis 29 1 2012 125 132
61. M. Sjögren, M. Blomberg, M. Jonsson, L.O. Wahlund, A. Edman, and K. Lind Neurofilament protein in cerebrospinal fluid: a marker of white matter changes J Neurosci Res 66 2001 510 516
62. J.P. Jia, R. Meng, Y.X. Sun, W.J. Sun, X.M. Ji, and L.F. Jia Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia Neurosci Lett 383 2005 12 16
63. D. de Jong, R.W. Jansen, B.P. Kremer, and M.M. Verbeek Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia J Gerontol A Biol Sci Med Sci 61 7 2006 755 758
64. N. Le Bastard, M. Van Buggenhout, E. De Leenheir, J.J. Martin, P.P. De Deyn, and S. Engelborghs Low specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate Alzheimer's disease from vascular dementia J Gerontol A Biol Sci Med Sci 62 2007 923 924
65. M. Bibl, B. Mollenhauer, H. Esselmann, M. Schneider, P. Lewczuk, and V. Welge Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review Dement Geriatr Cogn Disord 25 3 2008 256 265
66. J.L. Price, and J.C. Morris Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 1999 358 368
67. D. Strozyk, K. Blennow, L.R. White, and L.J. Launer CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 60 2003 652 656
68. A.M. Fagan, M.A. Mintun, R.H. Mach, S.Y. Lee, C.S. Dence, and A.R. Shah Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans Ann Neurol 59 2006 512 519
69. A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman, and A. Wall PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 2008 1456 1465
70. T. Grimmer, M. Riemenschneider, H. Forstl, G. Henriksen, W.E. Klunk, and C.A. Mathis Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid Biol Psychiatry 65 2009 927 934
71. K. Blennow, A. Wallin, and O. Hager Low frequency of postlumbar puncture headache in demented patients Acta Neurol Scand 88 1993 221 223
72. C. Rosén, O. Hansson, K. Blennow, and H. Zetterberg Fluid biomarkers in Alzheimer's disease-current concepts Mol Neurodegener 8 2013 20 30
73. P. Lewczuk, G. Beck, O. Ganslandt, H. Esselmann, F. Deisenhammer, and A. Regeniter International quality control survey of neurochemical dementia diagnostics Neurosci Lett 409 2006 1 4